- |||||||||| Jivi (damoctocog alfa pegol) / Bayer
Trial primary completion date, Interview: Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (clinicaltrials.gov) - Mar 15, 2017 P=N/A, N=30, Not yet recruiting, Recruiting --> Completed | Trial primary completion date: Jan 2017 --> Sep 2016 Trial primary completion date: Mar 2017 --> May 2017
- |||||||||| Fragmin (dalteparin sodium) / Pfizer, Eisai
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma (clinicaltrials.gov) - Mar 6, 2017 P2, N=13, Terminated, Trial primary completion date: Jan 2020 --> Mar 2023 N=30 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Dec 2016; Insufficient Accrual
- |||||||||| melphalan / Generic mfg., fludarabine IV / Generic mfg.
Enrollment closed, Trial initiation date, Trial primary completion date: Reduced Intensity Double Umbilical Cord Blood Transplantation (clinicaltrials.gov) - Mar 3, 2017 P2, N=33, Active, not recruiting, N=30 --> 13 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Dec 2016; Insufficient Accrual Recruiting --> Active, not recruiting | Initiation date: Sep 2011 --> Dec 2011 | Trial primary completion date: Aug 2016 --> Feb 2018
- |||||||||| Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion, Enrollment change, Trial primary completion date, Monotherapy: XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease (clinicaltrials.gov) - Feb 28, 2017 P1, N=4, Completed, Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=22 --> 4 | Trial primary completion date: Jun 2016 --> Aug 2014
- |||||||||| Phase classification, Enrollment change, Trial initiation date, Trial primary completion date: The Effect of the Nutraceutical "Hemofix" on the Coagulation System (clinicaltrials.gov) - Feb 23, 2017
P=N/A, N=0, Withdrawn, Trial primary completion date: Sep 2016 --> Sep 2017 Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020
- |||||||||| Xyntha (moroctocog alfa) / Pfizer
Trial completion, Phase classification, Enrollment change: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Feb 23, 2017 P=N/A, N=87, Completed, Phase classification: P1 --> P=N/A | N=40 --> 0 | Initiation date: Sep 2012 --> Sep 2016 | Trial primary completion date: Feb 2013 --> Jan 2020 Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=120 --> 87
- |||||||||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial initiation date, Trial primary completion date, Patient reported outcomes: ECHO: Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (clinicaltrials.gov) - Feb 23, 2017 P=N/A, N=2000, Recruiting, Active, not recruiting --> Completed | Phase classification: P4 --> PN/A | N=120 --> 87 Initiation date: Dec 2015 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| Onmel (itraconazole) / Merz Pharma
Trial completion: ATRA, Celecoxib, and Itraconazole as Maintenance (clinicaltrials.gov) - Feb 23, 2017 P1, N=1, Completed, Initiation date: Dec 2015 --> Dec 2016 | Trial primary completion date: Jun 2020 --> Dec 2020 Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: RVD Lite: Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (clinicaltrials.gov) - Feb 23, 2017 P2, N=53, Active, not recruiting, Trial primary completion date: Oct 2014 --> Jan 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment change, Trial termination, Trial primary completion date, Combination therapy: Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma (clinicaltrials.gov) - Feb 14, 2017 P1, N=9, Terminated, N=18 --> 9 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jul 2016; The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.
- |||||||||| Trial primary completion date: Control of Major Bleeding After Trauma Study (clinicaltrials.gov) - Feb 12, 2017
P2, N=150, Recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Apr 2017 --> Apr 2018
- |||||||||| Trial primary completion date, Surgery: INWOUND: Wound Healing Abnormalities in Major Abdominal Surgery (clinicaltrials.gov) - Feb 8, 2017
P=N/A, N=260, Recruiting, Recruiting --> Completed | N=48 --> 4 | Trial primary completion date: Nov 2018 --> Oct 2016 Trial primary completion date: Oct 2016 --> Apr 2017
|